These results, together with the possibility of determining p53 mutations and genic variants (including those of NR1D2) [52], as well as CSC-ctDNA [58], could mean a step forward in the diagnosis of tumour progression as well as response to treatment in CRC. This evidence concerns the gene NR1D2 and neoplasm.